For Media

Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.

8485088474098459398451958437428401018397688393318356358353490428079b-476a-4f2d-ab2e-88d1eabba7c151ac6f34-99db-47e9-973e-7040b2df72934d480b65-e669-4e35-bdae-2fd4e559740dda02f53c-7c62-4a0a-ab7d-70ac4950c5a578ce9e65-101b-4047-80f6-3579272a3497963a22e7-2f0b-4aa1-b3db-2c446fe0f93b9a5d6be7-eb98-4efc-a68e-8962f7242946eb2366b7-996c-4e98-83a7-09459c39c65e26322d45-e1ed-4540-ad8e-81fecc71ab7541be5706-ef4d-4b3f-9c5f-f05750561940ARGS_News_2015_9_1_General_Releases.pdfARGS_News_2015_8_24_General_Releases.pdfARGS_News_2015_8_12_General_Releases.pdfARGS_News_2015_8_10_General_Releases.pdfARGS_News_2015_8_5_General_Releases.pdfARGS_News_2015_7_21_General_Releases.pdfARGS_News_2015_7_17_General_Releases.pdfARGS_News_2015_7_15_General_Releases.pdfARGS_News_2015_6_16_General_Releases.pdfARGS_News_2015_6_15_General_Releases.pdf17408168022884345070143152113617457184261456717049123456789102015-9-1T8:30:0-4:02015-8-24T8:30:0-4:02015-8-12T16:5:0-4:02015-8-10T13:0:0-4:02015-8-5T8:30:0-4:02015-7-21T8:30:0-4:02015-7-17T8:30:0-4:02015-7-15T8:30:0-4:02015-6-16T16:30:0-4:02015-6-15T8:30:0-4:0929638928549927443926870925894922964922609922208918252917906General ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesGeneral ReleasesThe Company Will Share Perspectives on Clinical Development and Manufacturing of Individualized Immunotherapies.Single-Center Study is Enrolling Patients at Roswell Park Cancer Institute in Buffalo, New YorkInaugural Members Include Distinguished Oncologists and Immunologists to Provide Perspectives in Research and Development of Individualized Immunotherapies for the Treatment of CancerFully Personalized Immunotherapy is Being Evaluated in Combination With Standard Targeted Therapy for the Treatment of Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)Argos Therapeutics to Participate in Stem Cells and Regenerative Medicine Congress 2015Argos Therapeutics Awarded Patent for Its Experimental Individualized Immunotherapy for the Treatment of HIV InfectionArgos Therapeutics Reports Second Quarter 2015 Financial Results and Operational HighlightsArgos Therapeutics Announces Pilot Clinical Trial of AGS-003 as Neoadjuvant Immunotherapy for Localized Renal Cell CarcinomaArgos Therapeutics to Hold Second Quarter 2015 Financial Results Conference Call on Wednesday, August 12, 2015Argos Therapeutics Announces Formation of Scientific Advisory BoardArgos Therapeutics to Present at 8th IAS Conference on HIV Pathogenesis, Treatment and PreventionArgos Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003Argos Therapeutics to Present at the 2015 JMP Securities Life Sciences ConferenceArgos Therapeutics Hires John D. Menditto as Vice President of Corporate Communications and Investor Relations1111111111111111111111111111112015201520152015201520152015201520152015No Error0

Argos Therapeutics to Participate in Stem Cells and Regenerative Medicine Congress 2015
Read more

Argos Therapeutics Awarded Patent for Its Experimental Individualized Immunotherapy for the Treatment of HIV Infection
Read more

Argos Therapeutics Reports Second Quarter 2015 Financial Results and Operational Highlights
Read more

Argos Therapeutics Announces Pilot Clinical Trial of AGS-003 as Neoadjuvant Immunotherapy for Localized Renal Cell Carcinoma
Read more

Argos Therapeutics to Hold Second Quarter 2015 Financial Results Conference Call on Wednesday, August 12, 2015
Read more

Argos Therapeutics Announces Formation of Scientific Advisory Board
Read more

Argos Therapeutics to Present at 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention
Read more

Argos Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003
Read more

Argos Therapeutics to Present at the 2015 JMP Securities Life Sciences Conference
Read more

Argos Therapeutics Hires John D. Menditto as Vice President of Corporate Communications and Investor Relations
Read more